SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: RT who wrote (5198)2/1/1998 3:36:00 PM
From: Gene Voss  Read Replies (2) of 23519
 
RT: HVSF's patent does not infringe the Vivus patents because their claims are for something beside a transurethral application.They patented a lyophilized version of alprostadil but if sold as a transurethrally delivered product they will be infringing the "587" patent.Again don't trust me ask an atty.
The "problems" I refered to meant only to demonstrate that I felt anything could happen in business.I don't know of any specific problems but only a fool would expect smooth sailing for any new technology as this.I feel that the majority of the companies major obstacles have been addressed and circumstances will improve.
I understand your concern for HVSF and its product I don't mean to make any claims against them only to say their apparent threat to Vivus is minimal regardless of the outcome of any litigation.IMO

GV
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News